ATAXIA TELANGIECTASIA
Clinical trials for ATAXIA TELANGIECTASIA explained in plain language.
Never miss a new study
Get alerted when new ATAXIA TELANGIECTASIA trials appear
Sign up with your email to follow new studies for ATAXIA TELANGIECTASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Continued EryDex treatment studied in rare neurological disorder
Disease control TerminatedThis study offered continued treatment with EryDex to 101 people with ataxia telangiectasia (a rare genetic disease affecting coordination and immunity) who had finished a previous trial. The main goal was to track safety, such as side effects. The study was terminated early, and…
Matched conditions: ATAXIA TELANGIECTASIA
Phase: PHASE3 • Sponsor: Quince Therapeutics S.p.A. • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
Experimental drug shows promise for rare childhood movement disorder
Symptom relief TerminatedThis study tested a drug called N-Acetyl-L-Leucine (IB1001) in 17 people aged 6 and older with Ataxia-Telangiectasia (A-T), a rare genetic disease that causes severe movement problems. The goal was to see if the drug could safely improve coordination and slow the disease. The stu…
Matched conditions: ATAXIA TELANGIECTASIA
Phase: PHASE2 • Sponsor: IntraBio Inc • Aim: Symptom relief
Last updated May 26, 2026 12:09 UTC